Neurogene Earnings Call Transcripts
Fiscal Year 2026
-
NGN-401 is advancing in a pivotal trial for Rett syndrome, with durable, multi-domain functional gains observed and a 12-month endpoint required for approval. Commercial launch will leverage in-house manufacturing and a network of US centers, with Europe as a future opportunity.
-
NGN-401 gene therapy for Rett syndrome is advancing through a phase III trial, with Breakthrough Therapy designation and strong early data showing multi-domain developmental gains and no plateau at 12 months. The EXACT platform enables regulated gene expression, and safety protocols are robust. Enrollment is on track, with a midyear data update expected.
-
NGN-401, a gene therapy for Rett syndrome, is progressing through a pivotal study with enrollment and dosing set to complete in Q2 2026. Early data show durable, multi-domain improvements, and the company is preparing for US commercialization while planning for European expansion.
-
NGN-401, a gene therapy for Rett syndrome, is progressing rapidly through the Embolden registrational trial, with strong interim data showing durable, multi-domain improvements. Commercial readiness and market access strategies are advancing, targeting a multi-billion-dollar opportunity.
Fiscal Year 2025
-
Interim data for NGN-401 in Rett syndrome show durable, multi-domain skill gains and a favorable safety profile, with six of eight patients meeting responder criteria. Enrollment for the pivotal Embolden trial is on track to complete in 3–6 months, with strong regulatory alignment.
-
Recent FDA discussions enable imminent dosing in the embolden study, with ICV administration shown to deliver superior brain drug levels. Focus is on durable, multi-domain efficacy and early-age enrollment, with regulatory and trial design advantages supporting broad market potential.
-
NGN-401, a gene therapy for Rett syndrome, showed meaningful clinical improvements in early trials, with further data and regulatory updates expected in 2025. The program features unique technology and a strong safety protocol, with positive FDA engagement and cash runway into 2027.
-
NGN-401, a gene therapy for Rett Syndrome, is advancing under the FDA's START program, with a focus on single-arm trials using natural history controls due to ethical and practical challenges with placebo. Strong early efficacy and safety adjustments have shaped the trial, with regulatory and clinical updates expected this year.
-
Rett syndrome remains a high unmet need with no disease-modifying therapies. Interim phase 1/2 data for NGN-401 gene therapy showed meaningful, durable improvements in core symptoms and daily function. Regulatory discussions are ongoing, with a focus on single-arm or delayed start trial designs and enhanced safety monitoring.
Fiscal Year 2024
-
Interim phase I/II data for NGN-401 in Rett syndrome show all low-dose pediatric patients achieved unprecedented, durable improvements in core functional domains, with a strong safety profile and regulatory momentum for pivotal development.
-
A differentiated gene therapy platform is advancing two clinical programs, with Rett syndrome as the lead. The company was selected for the FDA's START program, enabling accelerated development, and expects key Rett data in Q4 2024.